CJC-1295

Read the suffix before the study

CJC-1295 is a synthetic peptide: a laboratory-made chain of amino acids, the small units that also make proteins. Its design follows part of growth hormone-releasing hormone. That natural signal reaches the pituitary, a gland under the brain that releases growth hormone.

DAC means drug affinity complex. It is a chemical attachment that allows a CJC-1295 form to bind albumin, a plentiful protein in blood. That changes how long the molecule remains present. The no-DAC form lacks this attachment. FDA treats these as different active ingredients, rather than interchangeable labels.

The FDA review of CJC-1295 forms also describes inconsistent naming as a safety concern. A paper’s molecule, a chemical specification, and a product name have to agree before findings can be compared. A familiar abbreviation alone cannot do that job.

What the human studies measured

In small studies of healthy adults, the DAC form produced sustained changes in growth hormone and IGF-1, a growth-related signaling protein. Researchers examined hormone measurements and safety. Higher concentrations of a hormone are a laboratory observation, not a health benefit by themselves.

These studies did not establish effects on sleep, body composition, injury recovery, or aging. FDA’s review found no human study of CJC-1295 without DAC. That leaves the no-DAC form with a different and much thinner evidence base than broad CJC-1295 summaries often suggest.

A study can be carefully conducted and still answer only a narrow question. Here the question involved hormone responses to a particular form in a small group. A larger claim would require different participants, relevant outcomes, and substantially more safety follow-up.

What remains outside the record

There is no established long-term human safety profile for the no-DAC form. The absence of a human study cannot reveal how often an adverse event happens or which interactions matter. It also leaves no basis for transferring the DAC form’s timing to another preparation.

CJC-1295 has no FDA-approved drug label. On the agency’s page current as of April 22, 2026, it appears among substances nominated but withdrawn, with safety concerns still listed. The page does not assign an individual withdrawal date. Taking back a nomination did not confer approval.

Anecdotal, not clinical evidence

Online accounts describe swelling, tingling, and local skin reactions. They often leave the chemical form unclear. That makes them especially poor evidence for comparing DAC with no DAC: the identity of the supposed comparison may already be uncertain.

The safety questions are still open

FDA describes concerns about faster heart rate, flushing-type reactions, and an immune response to the peptide or related impurities. An immune response means the body’s defenses recognize material as foreign. The agency also discusses risks associated with excess growth-hormone signaling.

These concerns are not a complete catalog of measured harms for every form. They explain why limited data cannot support a safety assurance. A batch test can help identify research material, but it cannot fill the missing human evidence or turn research supply into a medicine.